

## Correction

The following omissions were made in the article by Brooks *et al.* [Mol Cancer Ther 2003;2(11):1195–1205]: the first author's name should have appeared Tracy A. Brooks, the grant footnote should have cited support from Grant R21 CA98457 (to M. R. Baer), and the running head should have appeared as "Taxane-Based Reversal Agents: Multidrug Resistance Modulators." In addition, two terms within the article appeared incorrectly. The corrections in bold are as follows:

Abstract, sentence 7: "The four broad-spectrum tRAs strongly modulated daunorubicin and mitoxantrone efflux and enhanced their cytotoxicity in cell lines overexpressing the three **MDRs**, decreasing IC<sub>50</sub> values by as much as 97%."

Abstract, sentences 2 and 3; page 1196, paragraph 2, sentence 2: orataxel should have appeared **ortataxel**.

# Molecular Cancer Therapeutics

## Correction

*Mol Cancer Ther* 2004;3:101.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/3/1/101>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/3/1/101>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.